Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule

Piritrexim, an orally administered, lipid-soluble antifolate, was evaluated in a multi-institutional phase I trial in children. The starting dose was 10 mg/m2/dose administered every 8 h daily for 5 days for 3 consecutive weeks, with dose escalations in increments of 5 mg/m2/dose. Eighteen patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 1992-02, Vol.52 (3), p.521-524
Hauptverfasser:	ADAMSON, P. C, BALIS, F. M, MISER, J, ARNDT, C, WELLS, R. J, GILLESPIE, A, ARONSON, L, PENTA, J. S, CLENDENINN, N. J, POPLACK, D. G
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Antineoplastic agents Antineoplastic Agents - toxicity Biological and medical sciences Brain Neoplasms - drug therapy Chemotherapy Child Child, Preschool Drug Administration Schedule Drug Evaluation Female Glioma - drug therapy Humans Leukocyte Count - drug effects Male Medical sciences Neoplasms - drug therapy Pharmacology. Drug treatments Platelet Count - drug effects Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Pyrimidines - administration & dosage Pyrimidines - pharmacokinetics Pyrimidines - therapeutic use Pyrimidines - toxicity Sarcoma - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!